Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly has followed Novo Nordisk in announcing ... supporting products like GLP-1 agonist Trulicity (dulaglutide) and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

One of the highlights of Eli Lilly's third-quarter results was ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call.

Declining sales of Trulicity, rising pricing pressure on ... (You can read the full research report on Eli Lilly here >>>) Shares of S&P Global have outperformed the Zacks Business - Information ...

Declining sales of Trulicity and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. (You can read the full research report on Eli Lilly here >>>) Shares of ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...